ReviewThe American journal of pathology2015
Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.
Review in The American journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 89 citations in OpenAlex.
- Structural and proliferative responses of the prostate to abrupt versus tapered discontinuation of dutasteride in short- and long-term treated rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Microbial Genomic Consortia in Prostate Cancer: Mechanistic Signaling, the Gut-Prostate Axis, and Translational Perspectives.Cancers · 2026Review
- A scoping review of the role of heritability and environmental exposures in the development and severity of benign prostatic hyperplasia.Translational andrology and urology · 2025Review
- Review
- A randomized, active-controlled, multicenter, phase 3 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.Prostate international · 2025Article
- Network Pharmacology and Molecular Dynamics Identified Potential Androgen Receptor-Targeted Metabolites inInternational journal of molecular sciences · 2025Article
- The multifaceted role of the stroma in the healthy prostate and prostate cancer.Journal of translational medicine · 2024Review
- Arsenic-induced prostate cancer: an enigma.Medical oncology (Northwood, London, England) · 2024Review
- Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH.Journal of cellular and molecular medicine · 2023Article
- A novel co-culture model of human prostate epithelial and stromal cells for androgenic and antiandrogenic screening.Toxicology in vitro : an international journal published in association with BIBRA · 2023Article
- Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.The journal of pathology. Clinical research · 2023Article
- has_circ_0070512 promotes prostate cancer progression by regulating the miR-338-3p/hedgehog signaling pathway.Cancer science · 2023Article
- Androgens, aging, and prostate health.Reviews in endocrine & metabolic disorders · 2022Review
- Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.Molecules (Basel, Switzerland) · 2022Review
- METTL3 promotes prostatic hyperplasia by regulating PTEN expression in an mCell death & disease · 2022Article
- Stromal AR inhibits prostate tumor progression by restraining secretory luminal epithelial cells.Cell reports · 2022Article
- Prognostic value of prostate volume in non-muscle invasive bladder cancer.Scientific reports · 2021Article
- Effect of Kangquan Recipe () on BAMBI Expression in Hypothalamic-Pituitary-Prostate in Rats with Benign Prostatic Hyperplasia.Chinese journal of integrative medicine · 2021Article
- Animal models of benign prostatic hyperplasia.Prostate cancer and prostatic diseases · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
The prostate is an androgen-sensitive organ that needs proper androgen/androgen receptor (AR) signals for normal development. The progression of prostate diseases, including benign prostate hyperplasia (BPH) and prostate cancer (PCa), also needs proper androgen/AR signals. Tissue recombination studies report that stromal, but not epithelial, AR plays more critical roles via the mesenchymal-epithelial interactions to influence the early process of prostate development. However, in BPH and PCa, much more attention has been focused on epithelial AR roles. However, accumulating evidence indicates that stromal AR is also irreplaceable and plays critical roles in prostate disease progression. Herein, we summarize the roles of stromal AR in the development of normal prostate, BPH, and PCa, with evidence from the recent results of in vitro cell line studies, tissue recombination experiments, and AR knockout animal models. Current evidence suggests that stromal AR may play positive roles to promote BPH and PCa progression, and targeting stromal AR selectively with AR degradation enhancer, ASC-J9, may allow development of better therapies with fewer adverse effects to battle BPH and PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.